This Market Spotlight report covers the sickle cell anemia market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- The author estimates that in 2016, there were 3.2 million prevalent cases of sickle cell anemia worldwide, and forecasts for that number to increase to 3.5 million prevalent cases by 2025.
- Africa is estimated to have had 2.7 million prevalent cases of sickle cell anemia in 2016, accounting for 85% of worldwide cases.
- The majority of industry-sponsored drugs in active clinical development for sickle cell anemia are in Phase II. Therapies in mid- and late-stage development for sickle cell anemia focus on targets such as hemoglobin and selectins, adenosine diphosphate P2Y12 receptor, nuclear factor-kappa beta, and nuclear erythroid 2-related factor 2. More than half of the pipeline drugs in mid-to-late-stage development for sickle cell anemia are administered via the intravenous/oral route.
- Endari (levoglutamide), a patented drug treatment that involves an oral administration of L-glutamine, is the only US Food and Drug Administration approved drug for sickle cell anemia.
- The high impact upcoming events in the sickle cell anemia space include top-line Phase III trial results for GBT440 and Altemia. Licensing and asset acquisition activity involving sickle cell anemia drugs has been weak during 2012-17, with only eight deals occurring over this time period. The $2,520m strategic research collaboration deal between Vertex Pharmaceuticals and CRISPR Therapeutics for the discovery and development of drugs based on CRISPR-Cas9 technology, was the largest deal during 2012-17. Brilinta sales have ranked highest in the sickle cell anemia space during 2012-16.
- The clinical trials distribution across Phase I-IV indicates that the majority of the drugs are in early and mid phases of development with 81% of trials in Phase I-II, and only 19% in Phase III-IV.
- While the US has a substantial lead in the number of sickle cell anemia clinical trials globally, the UK leads the major EU markets. Clinical trial activity in the sickle cell anemia space is dominated by completed trials, with only 30% of ongoing trials. Pfizer, Eli Lilly and Novartis have the highest number of completed clinical trials for sickle cell anemia number of clinical trials for cervical cancer, followed by Roche.
Key Topics Covered:
1 Key Takeaways
2 Disease Background
5 Pipeline Drugs
6 Marketed Drugs
7 Key Upcoming Events
8 Key Regulatory Events
9 Licensing And Asset Acquisition Deals
10 Parent Patents
11 Clinical Trial Landscape
For more information about this report visit https://www.researchandmarkets.com/research/6n7tfp/market_spotlight